Send to

Choose Destination
MAbs. 2016 Aug-Sep;8(6):1010-20. doi: 10.1080/19420862.2016.1197457. Epub 2016 Jun 10.

The use of CrossMAb technology for the generation of bi- and multispecific antibodies.

Author information

a Roche Innovation Center Zurich , Roche Pharmaceutical Research & Early Development, Wagistrasse , Schlieren , Switzerland.
b Roche Innovation Center Munich , Roche Pharmaceutical Research & Early Development, Nonnenwald , Penzberg , Germany.


The major challenge in the generation of bispecific IgG antibodies is enforcement of the correct heavy and light chain association. The correct association of generic light chains can be enabled using immunoglobulin domain crossover, known as CrossMAb technology, which can be combined with approaches enabling correct heavy chain association such as knobs-into-holes (KiH) technology or electrostatic steering. Since its development, this technology has proven to be very versatile, allowing the generation of various bispecific antibody formats, not only heterodimeric/asymmetric bivalent 1+1 CrossMAbs, but also tri- (2+1), tetravalent (2+2) bispecific and multispecific antibodies. Numerous CrossMAbs have been evaluated in preclinical studies, and, so far, 4 different tailor-made bispecific antibodies based on the CrossMAb technology have entered clinical studies. Here, we review the properties and activities of bispecific CrossMAbs and give an overview of the variety of CrossMAb-enabled antibody formats that differ from heterodimeric 1+1 bispecific IgG antibodies.


2+1, 1+1; 2+2; Ang-2; CEA TCB; CrossMAb; DAF-CrossMAb; DVD-CrossMAb; DuoMAb; EGFR; HER1; HER3; Immunoglobulin domain crossover; Kappa-Lambda-CrossMAb; MoAb; MoAb-Dimer; MonoMAb; P329G LALA; RG7221; RG7386; RG7716; RG7802; Triple A; VEGF-A; asymmetric; heterodimeric; knobs-into-holes (KiH); vanucizumab

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center